Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 17, 2019
The Company announced today the Board of Directors has appointed Craig Tooman to serve as President and Chief Executive Officer of Aratana, and elected Tooman to the Board of Directors.
-
Nov 1, 2018
Aratana announced its third quarter 2018 financial results, reporting total net revenues of $21.6 million and net income of $8.8 million or $0.19 diluted earnings per share.
-
Oct 22, 2018
Aratana will host a live conference call on Friday, November 2, 2018 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2018.
-
Aug 29, 2018
The Company plans on presenting at CL King & Associates Best Ideas Conference on Thursday, September 13, 2018 at 1:15 p.m. ET in New York City.
-
Aug 2, 2018
Aratana announced its second quarter 2018 financial results, reporting total net revenues of $4.9 million and a net loss of $6.4 million or $0.14 diluted loss per share.
-
Jul 10, 2018
The Company will host a live conference call on Friday, August 3, 2018 at 8:30 a.m. ET to discuss financial results from the second quarter ended June 30, 2018.
-
Jun 1, 2018
Aratana submitted a supplemental New Animal Drug Application (NADA) for NOCITA® (bupivacaine liposome injectable suspension) with the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) to expand the NOCITA label to include its use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy.
-
May 22, 2018
The Company plans on presenting at Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 4:30 p.m. ET in New York City.
-
May 21, 2018
The Company has appointed Craig Barbarosh and Lowell Robinson to its Board of Directors in connection with a cooperation agreement with Engaged Capital, LLC.
-
May 3, 2018
Aratana announced its first quarter 2018 financial results, reporting total net revenues of $4.0 million and a net loss of $8.5 million or $0.19 diluted loss per share.